Taro delivered a strong outperformance on the revenue and operating margins front. Revenue was up 43% at USD159mn (estimated USD148mn) while gross margins at 71.7% was higher than the estimated 69%. Operating margins were at 49.6%, up 19%YoY and 4%QoQ (estimated 44%). PAT of USD63mn was up 72% against the estimated USD55mn, which would have a positive impact on Sun Pharma (SUNP) Q1FY13 numbers.
